Market closed

Mersana Therapeutics/$MRSN

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Mersana Therapeutics

Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.

Ticker

$MRSN
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Cambridge, United States

Employees

123
Website
www.mersana.com

MRSN Metrics

BasicAdvanced
$77M
-
-$0.61
1.47
-

$77M

1.47

$6.28

$0.60

4M

2.351

2.287

1,555.291

3,005.338

-11.28%

-22.97%

-280.29%

2.173

72.8

72.8

-0.792

-14.70%

-65.43%

832.23%

-34.19%

What the Analysts think about MRSN

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Mersana Therapeutics stock.

MRSN Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

MRSN Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

MRSN News

AllArticlesVideos
Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)

Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)

GlobeNewsWire·5 days ago
Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer

Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer

GlobeNewsWire·5 days ago
Mersana Therapeutics: We're About To Find Out If ADC Platform Is More Tolerable

Mersana Therapeutics: We're About To Find Out If ADC Platform Is More Tolerable

Seeking Alpha·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MRSN

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Mersana Therapeutics stock?

Mersana Therapeutics (MRSN) has a market cap of $77M as of January 15, 2025.

What is the P/E ratio for Mersana Therapeutics stock?

The price to earnings (P/E) ratio for Mersana Therapeutics (MRSN) stock is 0 as of January 15, 2025.

Does Mersana Therapeutics stock pay dividends?

No, Mersana Therapeutics (MRSN) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Mersana Therapeutics dividend payment date?

Mersana Therapeutics (MRSN) stock does not pay dividends to its shareholders.

What is the beta indicator for Mersana Therapeutics?

Mersana Therapeutics (MRSN) has a beta rating of 1.47. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.